Use of CD24 for lowering low-density lipoprotein cholesterol levels
AssigneeOncoimmune, Inc.
InventorsYang Liu, Pan Zheng
Life of this patent
Estimating the term…
Abstract
The present invention relates to the use of a CD24 protein for lowering low-density lipoprotein cholesterol levels, treating and preventing atherosclerosis, and for reducing risk of cardiovascular disease.
Claims21
A method of reducing low-density lipoprotein (LDL) cholesterol (LDL-C) levels in a human subject in need thereof, comprising administering a CD24 protein to the subject, wherein the CD24 protein comprises:
- (a) a mature human CD24 polypeptide comprising the sequence set forth in SEQ ID NO:
- 1 or 2;
- and, (b) a Fc region of a human IgG protein;
- and, wherein the Fc region is fused at the C-terminus of the CD24 protein.
A method of treating atherosclerosis in a human subject in need thereof, comprising administering a CD24 protein to the subject, wherein the amino acid sequence of the CD24 protein consists of SEQ ID NO:
- 6, 11, or 12.
A method of lowering the risk of atherosclerotic cardiovascular disease in a human subject in need thereof, comprising administering a CD24 protein to the subject, wherein the amino acid sequence of the CD24 protein consists of SEQ ID NO:
- 6, 11, or 12.
A method of reducing LDL-C levels in a human subject in need thereof, comprising administering to the subject a CD24 protein consisting of the sequence set forth in SEQ ID NO:
- 6.
Dependencies are inferred from the claim text.